BioWorld MedTech

Nov. 7, 2011

NewCo on the Block: CerviLenz offers screening tool for preterm birth risk

CerviLenz (Chagrin Falls, Ohio), a woman's health device company in the Cleveland area, has recently bumped its Series A round of investment up to $8.35 million, thanks to a recent tranche of funding from existing investors. Read More

Report from Europe: Ziehm Imaging reports the opening of French sales office

Spinal USA continues down path of growth with 2 recent approvals

Washington roundup: Industry urges CMS to revisit criteria for pass-through codes

Deals roundup: Siemens to acquire HIE developer MobileMD

Agreements/contracts: Bluewater enters western distribution with SurgLine

MDD's Fast Facts

NASS notebook: Medtronic Spinal launches T2 Altitude at NASS conference

Med-Tech Notes: GE Capital reports $5B in healthcare financing

Financings roundup: Tenet launches tender offer for 9% senior notes due 2015

HIT roundup: Nortec to support health IT in underserved communities

Med-Tech Notes: Study: no link between diabetes and kidney stones

Med-Tech Notes: U of Iowa to use GE 7T MRI for brain research

Product Briefs

People in the News

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...